Abstract. Human catechol-O-methyltransferase (COMT, EC 2.1.1.6) catalyzes the transfer of the methyl group to a variety of endogenous and exogenous catechol substrates using Sadenosyl-L-methionine as the methyl donor. This enzymatic O-methylation plays an important role in the inactivation of biologically-active and toxic catechols. A number of studies in recent years have sought to characterize the polymorphism of human COMT, and also to determine the catalytic activity of polymorphic enzymes. We report here the identification of a new haplotype of the human COMT gene with triplet point mutations, which encodes the D51G/S60F/K162R mutant of the soluble COMT and the D101G/S110F/K212R mutant of the membrane-bound COMT. Kinetic analysis showed that these new COMT variants had essentially the same kinetic characteristics and catalytic activity as the wild-type COMTs for the O-methylation of 2-hydroxyestradiol and 4-hydroxyestradiol in vitro, but they have a significantly reduced thermostability at 37˚C. In addition, the mutant enzymes have different binding affinities for S-adenosyl-L-methionine compared with the wild-type COMTs. In agreement with our biochemical observations, molecular modeling studies also showed that the variant human COMT proteins shared nearly the same overall structures as the wild-type proteins. The binding energy values of the mutant COMTs in complex with catechol estrogen substrates were similar to those of the wildtype COMTs bound with the same substrates.
Introduction
Human catechol-O-methyltransferase (COMT; EC 2.1.1.6) catalyzes the transfer of the methyl group to a wide variety of endogenous and exogenous catechol substrates by using Sadenosyl-L-methionine (AdoMet) as the methyl donor (1) (2) (3) (4) (5) (6) (7) (8) .
In the central nervous system, COMT metabolically deactivates catecholamine neurotransmitters (dopamine and norepinephrine) through O-methylation. The human COMT exists in two different forms, the soluble form (S-COMT) and the membrane-bound form (MB-COMT), which are encoded by a single gene (8, 9) . A decrease in the methylation of catecholamine neurotransmitters due to the presence of a thermolabile S-COMT variant (V108M) has been associated with an increased risk for Parkinson's disease (3, 9) , the development of a chronic pain condition (10) (11) (12) , and also a number of mental disorders (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . In addition to catecholamine neurotransmitters, the endogenous catechol estrogens, such as 2-and 4-hydroxyestradiol (2-OH-E 2 and 4-OH-E 2 ), which are major oxidative metabolites of 17ß-estradiol (E 2 ) formed by cytochrome P450 isoforms in humans (22, 23) , are also rapidly O-methylated by COMT, in a manner analogous to the O-methylation of catecholamines (21) . A number of studies have demonstrated that metabolic O-methylation provides effective inactivation/detoxification of the procarcinogenic catechol estrogen intermediates. The major O-methylation product of 2-OH-E 2 (2-methoxyestradiol) has strong apoptotic, antiangiogenic, and anticancer actions [reviewed in refs. (3, 24) ]. Hence, metabolic O-methylation of catechol estrogens may not only inactivate the catechol estrogen intermediates, but may also simultaneously produce 2-methoxyestradiol that has significant anticancer activity (24) . These two concurrent processes are thought to be beneficial for reducing the risk of estrogen-induced cancers (24) . In line with this suggestion, many epidemiological studies have shown that women, homozygous with a thermolabile variant (V108M) of S-COMT, have an increased risk of estrogen-associated cancers (25) (26) (27) (28) (29) (30) (31) (32) , thus providing support for this interesting hypothesis.
Given the potentially important biological consequences associated with a reduced COMT catalytic activity in vivo, a number of studies in recent years have sought to investigate the polymorphism of the human COMT gene, as well as its effect on the catalytic activity of the enzyme (33) (34) (35) (36) (37) . At present, a total of 14 polymorphisms (summarized in Table I) are listed in the NCBI SNP database for the coding regions (exons) of the human COMT gene, and each of them are single point mutations. Among them, only three of the COMT mutants have been studied for their enzymatic activity and functional differences with the wild-type COMT. The V108M mutant of human S-COMT was found to retain nearly the same catalytic ability for the O-methylation of catechol estrogen substrates as the wild-type COMT, but it had a reduced thermostability (32) (33) (34) (35) (36) . In comparison, the A22S mutant of the human S-COMT had a lower catalytic activity and also reduced thermostability (37) .
In the present study, we identified a new haplotype of the human COMT gene. In addition, we have selectively expressed the wild-type and mutant human S-and MBCOMTs in Escherichia coli (E. coli) for comparing their biochemical characteristics for the O-methylation of endogenous catechol estrogens. Using S-COMT as an example, we additionally conducted computational molecular modeling studies to compare the structural and catalytic differences between the wild-type and variant enzymes.
Materials and methods
Chemicals. 2-OH-E 2 , 4-OH-E 2 , isopropylthio-ß-D-galactoside (IPTG), 1,4-dithiothreitol (DTT) and phenylmethylsulfonyl fluoride (PMSF), S-adenosyl-L-methionine (AdoMet) were purchased from Sigma-Aldrich (St. Louis, MO). (Methyl-3 H) AdoMet (specific activity, 11.2-13.5 Ci/mmol) was obtained from Perkin Elmer (Waltham, MA). All solvents used in this study were of HPLC grade or higher and were obtained from Fisher Scientific Co. (Springfield, NJ).
Cloning of human S-COMT and MB-COMT cDNAs.
The human liver cDNA library, obtained from Stratagene (La Jolla, CA), was generated from pooled normal liver tissues from two females, and was used as a template for cloning the human S-COMT and MB-COMT cDNAs. For PCR, the 5' complementary forward primers (5'-CAA CAT ATG CCG GAG GCC CCG-3' and 5'-GCA TAT GCC GGA GGC CCC GCC TC-3') were used for S-COMT and MB-COMT, respectively, along with a common 3' reverse primer (5'-CAG GAT CCT CAG GGC CCT GCT-3'). These primers were specifically designed to append the sequence that contains a 5' NdeI restriction site and a 3' BamHI restriction site (Fig. 1, lower panel) . The resulting 655-bp fragment for S-COMT and the 815-bp fragment for MB-COMT amplified by PCR were eluted using a gel extract kit (Qiagen, Valenica, CA), and they were then ligated to the pGEM T vector (Promega, Madison, WI) using T4 ligase (Invitrogen, Carlsbad, CA). The products of the ligation reactions were transformed into the chemically competent E. coli TOP-10F' cells (Invitrogen, Carlsbad, CA), and the transformed bacteria were then selected with ampicillin (50 μg/ml) on LB agar plates. The plasmids were purified using a Miniprep purification kit (Qiagen, Valencia, CA). The entire S-COMT and MB-COMT cDNA sequences were determined for verification. Note that three different types of DNA polymerase, i.e., ExTaqDNA polymerase (Takara, Madison, WI), PfuTurbo DNA polymerase (Staratagene, La Jolla, CA), and HotStarTaq DNA polymerase (Qiagen, Valencia, CA), all of which have high fidelity and proof-reading capability, were used for the PCR for cloning the human S-COMT and MB-COMT cDNAs. The resulting cDNA products from three different DNA polymerases were sequenced and the sequences matched each other. In addition, the sequences of the overlapping regions of the S-COMT and MB-COMT cDNAs also matched each other.
The plasmids were then restriction-digested with NdeI and BamHI and ligated into NdeI and BamHI-digested pET12a vector (Novagen, Madison, WI). The recombinant Table I . The COMT polymorphisms listed in the NCBI SNP database (http://www.ncbi.nlm.nih.gov/SNP). 
a These nucleic acid mutations will not alter the amino acids that are encoded by the altered codons.
DNAs were introduced into chemically competent E. coli BL21 (DE3) (Novagen, Madison, WI) according to the procedures recommended by the manufacturer, and the transformed cells were selected with ampicillin (50 μg/ml) on LB agar plates.
In vitro site-directed mutagenesis. The cDNAs of the cloned mutant human S-COMT (D51G, S60F and K162R) and MB-COMT (D101G, S110F and K212R) were used as templates to generate the corresponding wild-type cDNAs. The mutations were corrected by using a PCR-based site-directed mutagenesis using the QuikChange multisite-directed mutagenesis kit (Stratagene, La Jolla, CA). The site-directed mutagenesis was carried out according to the procedures recommended by the manufacturer with the following primers: 5'-GGCAAGATCGTGGACGCCGTGATTC-3' for D51/101G, 5'-CACCAGCCCTCCGTGCTGCTGGAGC-3' for S60/110F, and 5'-CTGCTGCGGAAGGGGACAGTGC TAC-3' for K162/212R. The sequences of reconstructed plasmid DNAs were confirmed by DNA sequencing.
Bacterial expression of recombinant human COMTs. For the expression of the recombinant human S-and MB-COMT proteins in E. coli BL21 (DE3, expressing T7 polymerase), positive clones were first cultured in the LB medium supplemented with ampicillin (50 μg/ml) overnight at 37˚C. The culture broth was then inoculated into 300 ml fresh LB medium supplemented with ampicillin and incubated at 37˚C with vigorous shaking until the optical density reading of the bacterial culture mixture achieved ~0.6 (at λ=600 nm). The culture was then induced with isopropylthio-ß-D-galactoside (at a final concentration of 0.5 mM) and cultured for another 3 h. The cells were collected by centrifugation and were then sonicated in ice-cold lysis buffer (50 mM Tris-HCl, pH 7.5 + 200 mM NaCl). After the addition of 5 mM 1,4-dithiothreitol and 1 mM phenylmethylsulfonyl fluoride to the crude homogenates, they were centrifuged at 10,000 x g for 10 min at 4˚C. The supernatants were then subjected to column purification or directly stored at -80˚C.
Assay of the enzyme activity and thermostability of recombinant human COMTs in vitro.
The catalytic activity of the wild-type and mutant human recombinant S-and MBCOMTs was determined at 37˚C as described earlier (38) . The reaction mixtures consisted of the recombinant COMT protein (at 16.2 μg/ml for S-COMT or 17.1 μg/ml for MB-COMT), 1.2 mM MgCl 2 , 100 μM AdoMet (containing 0.5 mCi [methyl-3 H]AdoMet), 1 mM 1,4-dithiothreitol, and 2-OH-E 2 or 4-OH-E 2 as substrate (at 10 μM or as indicated) in TrisHCl buffer (50 mM, pH 7.4). The final volume of the reaction mixture was 300 μl. The reaction was initiated by the addition of recombinant human COMT protein and carried out at 37˚C for 15 min. To test the thermo-stability of the mutant and wild-type COMTs, the enzymes were first preincubated at 37˚C for the indicated length of time immediately before testing their catalytic activity for the Omethylation of 2-OH-E 2 (at 10 μM). The reaction was arrested by immediately placing the tubes on ice and followed by addition of 500 μl ice-cold saline. The reaction mixtures were extracted with 5 ml ethyl acetate for the methylated catechol products. After centrifugation at 1000 g for 10 min, portions of the organic extracts were measured for radioactivity content with a liquid scintillation analyzer (Packard Tri-CARB 2900TR, Downers Grove, IL). The rate of methylation of a substrate was expressed as 'nmol of methylated product formed/mg of human COMT protein/ minute' (abbreviated as 'nmol/mg protein/min'). The kinetic parameters (K M and V MAX values) were calculated by using the curve regression method of the SigmaPlot program.
Construction of the homology models for human wild-type and mutant S-COMTs. Homology modeling was performed using the InsightII modeling program (Version 2005, Accelrys Inc., San Diego, CA) on a Dell Precision 690 workstation installed with Red Hat Enterprise Linux WS4.0 operating system (Red Hat Inc., Raleigh, NC). The energy minimization and molecular dynamics simulation were performed with Discovery Studio modeling program (Version 1.7, Accelrys Inc., San Diego, CA). The CHARMm force field was used for energy minimization and dynamics simulation.
The primary sequences of human S-COMT (GeneBank accession no. NM007310) and rat S-COMT (GeneBank accession no. BC081850) were obtained from the NCBI database. Sequence alignments were performed by using the Homology Modeling module of InsightII, which showed a ≥80% sequence similarity. The homology model of the human S-COMT was constructed according to the rat S-COMT (PDB code: 1VID) by using the Modeler in the Homology Modeling module of InsightII. The substrate 3,5-dinitrocatechol, AdoMet, Mg 2+ ion, and the crystallographic H 2 O that coordinates with Mg 2+ were included in the homology model. The simulation was carried out using the Standard Dynamics Cascade protocol in the Discovery Studio. For energy minimization, the steepest descent method was employed first to a 10 kcal/(molÅ) root mean square gradient and followed by the Polak and Ribiere conjugate gradient method until the final convergence criterion achieved 0.01 kcal/(molÅ) gradient. Then the whole system was heated from 50 to 300 K in 2 ps and equilibrated in 300 K for 100 ps. One hundred conformations were collected in 20-ps production phase at 300 K. The conformation with the lowest potential energy was further minimized and used for binding energy analysis. 3,5-Dinitrocatechol, Mg 2+ , H 2 O, AdoMet and key residues in the catalytic site (D141, K144, D169, N170 and E199) were constrained during the simulation process.
It should be noted that the structure of the D51G/ S60F/K162R mutant human S-COMT was built with the Build Mutant function of the Homology Modeling module by using two different methods: one was based on the homology model of the wild-type human S-COMT that was built in the present study and the other was based on the crystallographic structure of the rat S-COMT (PDB code: 1VID). The same simulation process was carried out when we built the structures of the mutant or wild-type S-COMT.
Calculation of the binding energy values (ΔE binding ) of S-
COMTs with substrates. The structures of 2-OH-E 2 and 4-OH-E 2 were built with the Builder module of InsightII based on the X-ray structure of E 2 (PDB code: 1ERE) and minimized with CHARMm force field. The catechol ring of the substrates was superimposed onto the catechol ring of 3,5-dinitrocatechol. The simulation was carried out with the Standard Dynamics Cascade protocol in Discovery Studio. The same simulation cascade was carried out as the cascade that was used for building the human COMT in complex with 3,5-dinitro-catechol as ligand. One hundred conformations were collected in the 20-ps production phase at 300 K. The conformation with the lowest potential energy was further minimized and used for the Binding Energy Calculation protocol. The backbone of the protein, key residues in the catalytic site (D141, K144, D169, N170 and E199), the catechol ring of the substrate, AdoMet, Mg 2+ , and H 2 O were constrained during the whole simulation process. ΔE binding was calculated with the following equation: ΔE binding = E complex -(E COMT + E substrate ), where E complex is the potential energy for the complex of human COMT with its substrate, E COMT is the potential energy of the enzyme itself and E substrate is the potential energy for the substrate itself.
Results

Cloning of the mutant human S-and MB-COMT cDNAs.
In the present study, the human S-and MB-COMT cDNAs were selectively amplified with PCR using the human liver cDNA library as a template. After the recombinant plasmids containing the cDNA for human S-COMT or MB-COMT were enzymatically digested, gel electrophoresis of the digests revealed that the DNA fragment bands matched the expected sizes of 655 and 815 bp, respectively (data not shown). The full-length sequence analysis of the cloned cDNAs was performed to determine their sequences. By comparing with sequences of NM_000754 and NM_007310, which were used as standards for the wild-type human S-COMT and MB-COMT, respectively, we found that the sequences were changed at three places for S-COMT and MB-COMT cDNAs, and the changes were at the same positions for the two of them. As noted earlier, three different types of DNA polymerase, each with high fidelity and proofreading capability, were used in this study for the PCR for cloning the human S-COMT and MB-COMT cDNAs. The resulting cDNA products from three different DNA polymerases were sequenced and the same sequence was obtained. Notably, since it is known that a single gene [localized to chromosome 22, band q11.2 (8,9)] encodes human S-and MB-COMT proteins by using two separate promoters (6), we believe that the triplet point mutations of the human S-and MB-COMT cDNAs were not artificial errors produced during the cloning procedures, as the exact same triplet point mutations were seen in the cDNAs of S-COMT (D51G/S60F/K162R) and MB-COMT (D101G/ S110F/K212R). The likelihood of their occurrence as a result of experimental errors was very low.
To obtain the wild-type human S-and MB-COMT cDNAs, we carried out PCR-based site-directed mutagenesis based on the mutant human S-and MB-COMT cDNAs. The full-length DNA sequences were determined twice and compared with the known wild-type human COMT gene. The DNA sequencing results confirmed their right sequences.
Expression of the mutant and wild-type COMT proteins in E. coli. The E. coli BL21 (DE3) cells were transformed with the recombinant expression vector pET12a containing the gene encoding either the mutant or wild-type human S-COMT or MB-COMT. Following induction with 0.5 mM isopropylthio-ß-D-galactoside, the bacteria that abundantly expressed the desired protein were harvested by centrifugation. The resulting cell pellets were lysed and analyzed using 12% SDS-PAGE, followed by Western blot analysis using polyclonal rabbit antibodies against the human wild-type COMT and donkey anti-rabbit IgG antiserum (conjugated to horseradish peroxidase).
A band with a molecular mass of ~24 kD was detected for mutant and wild-type S-COMT proteins, and a band of ~30 kD was detected for the mutant and wild-type MB-COMTs (data not shown). The sizes of the expressed proteins matched the expected sizes for the recombinant human S-and MB-COMT proteins. Table II . A comparison of the kinetic parameters of the mutant forms of the human S-and MB-COMTs with those of wildtype human S-and MB-COMTs. 
Kinetic parameters for the O-methylation of 2-OH-E
----------------------------------------------------------------------------------------------------- Genotype Substrate (μM) AdoMet (μM) K M (μM) V MAX V MAX /K M (nmol/mg/min) -
----------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
a To determine the apparent K M and V MAX values of AdoMet for the O-methylation catalyzed by S-COMT and MB-COMT, a fixed concentration (at 10 μM) of 2-OH-E 2 or 4-OH-E 2 was used as a substrate, and different concentrations of AdoMed (at 0, 12.5, 25, 50, 100, 200, and 400 μM) were used as the methyl donor.
-----------------------------------------------------------------------------------------------------
and V MAX /K M ) of the mutant human S-and MB-COMTs, we selectively expressed them and also the wild-type S-and MB-COMTs in E. coli. The enzyme activity assays were performed by measuring the COMT-mediated O-methylation of 2-OH-E 2 and 4-OH-E 2 , two representative endogenous catechol estrogen substrates. No significant difference was observed between the wild-type S-COMT and its D51G/ S60F/K162R mutant form, or between the wild-type MB-COMT and its D101G/S110F/K212R mutant form (Fig. 2 and Table II) .
When a fixed concentration of 2-OH-E 2 or 4-OH-E 2 (at 10 μM) was used as a substrate, the apparent K M values of the wild-type S-COMT for AdoMet were 113.6 or 145.3 μM, respectively (Fig. 3) . Under the same conditions, the apparent K M values of the D51G/S60F/K162R mutant of human S-COMT for AdoMet were 79.5 and 146.7 μM. Notably, the K M value of the mutant S-COMT for AdoMet in the Omethylation of 2-OH-E 2 (but not 4-OH-E 2 ) was ~50% lower than the corresponding K M value for the wild-type S-COMT (Table II) .
We have also compared the sensitivity of the mutant and wild-type human S-COMTs to inhibition by AdoHcy (a physiological feedback inhibitor of COMTs) on the Omethylation of 2-OH-E 2 and 4-OH-E 2 . The mutant D51G/S60F/K162R S-COMT was less sensitive to inhibition by AdoHcy for the O-methylation of 2-OH-E 2 as compared to the wild-type S-COMT (IC 50 values of 18.4 and 6.07 μM, respectively, Fig. 4 ). However, AdoHcy had a comparable potency for inhibiting the O-methylation of 4-OH-E 2 by the wild-type S-COMT and its D51G/S60F/K162R mutant (the IC 50 values of 22.6 and 29.6 μM, respectively) (Fig. 4) .
Thermostability test. The thermostability of human COMTs has often been used as an indicator of the biophysical properties of the mutant COMT proteins. In the present study, we also compared the thermostability of the mutant human S-and MB-COMTs with the wild-type COMTs. The D51G/S60F/K162R mutant S-COMT and the D101G/ S110F/K212R mutant MB-COMT were more sensitive to inactivation after pre-incubation at 37˚C. The mutant S-COMT and MB-COMT lost ~60% of their catalytic activity after pre-incubation at 37˚C for 120 min, while the wild-type enzymes were mostly stable after up to 120 min of preincubation at 37˚C (Fig. 5) .
Notably, the thermostability of the S60F/K162R mutant S-COMT, which has one of the three point mutations corrected by site-directed mutagenesis, was completely restored to that of the wild-type COMT (data not shown). These data showed that the aspartate residue at position 51 (D51) of the human S-COMT plays a crucial role in determining its thermostability.
Molecular modeling.
To better understand the mechanism of the triplet point mutations in affecting the structure and catalytic activity of human COMTs, we constructed the homology models for wild-type and mutant human SCOMTs. Two different methods were used to build the mutant human S-COMT. One of them used the human S-COMT homology model as a template to build the structure 4 -dithiothreitol, and the recombinant COMT protein (at 16.2 μg/ml for S-COMT or 17.1 μg/ml for MB-COMT). The incubations were carried out at 37˚C for 15 min. Note that the rate of its total methylation was based on the liquid scintillation counting of the radioactivity extracted with ethyl acetate. The rates for its 2-O-and 3-Omethylation (C and F) were determined by using HPLC that separately quantified the amount of 2-methoxyestradiol (2-MeO-E 2 ) and 2-OH-E 2 3-methyl ether (2-OH-3-MeO-E 2 ) formed. Each value is the mean of duplicate measurements.
of the mutant S-COMT. This method has been commonly used in many other similar studies. In addition, we also built de novo the structure of the mutant human S-COMT according to the known crystallographic structure of the rat S-COMT. The use of two different methods was hoped to provide a more complete view of the possible structures of this new mutant human COMT. Our homology models showed that the two mutant S-COMT homology models built with two different templates are nearly the same in their backbone structures as well as their catalytic sites (Fig. 6) , with only minor differences in the side-chain orientations. Therefore, for further structural comparison with the wildtype human S-COMT as well as for docking calculations using representative substrates, the mutant S-COMT built according to the wild-type human S-COMT was used.
When the enzyme was complexed with a representative substrate and also the methyl donor AdoMet, the secondary structures of the wild-type and mutant S-COMTs were nearly identical (Fig. 6) . Although the S60F mutation caused some minor changes in loop 5 which connects α-helix 4 and ß-sheet 2, the overall structure and configuration of the nine α-helixes and seven ß-sheets remained mostly the same. The amino acid residue D51 in the wild-type S-COMT was located in α-helix 3, and S60 and K162 were located in two different loop regions (loops 3 and 11, respectively). A comparison of homology-modeled structures of the wild-type and mutant form showed that the D51G mutation did not noticeably interrupt the structure of α-helix 3 of the enzyme, and similarly, the S60K and K162R mutations also did not significantly affect the overall structure of the enzyme. Notably, these three mutations are mostly located in the outer surface regions of the COMT protein, and they are on the opposite side of the catalytic pocket. The distances between the α-carbon of D51, S60 and K162 to Mg 2+ are 13.8, 23.2 and 25.2 Å, respectively, which are beyond the defined catalytic site (within the 7-Å reach of the Mg 2+ ion). The structures of the catalytic sites in the wild-type and mutant COMTs are nearly identical when they are in complex with 2-OH-E 2 or 4-OH-E 2 . In addition, the orientations of the two substrates are very similar when they are bound as a substrate in the catalytic pocket.
Using the homology models we developed, we also computed the relative binding energy values (ΔE binding ) of the wild-type and mutant human COMTs for 2-OH-E 2 and 4-OH-E 2 . We found that 2-OH-E 2 and 4-OH-E 2 have similar binding energy values for the wild-type and mutant S-COMTs (data summarized in Table III) . When 2-OH-E 2 was the substrate, the ΔE binding values for its interactions with the wild-type and mutant S-COMTs for its 2-O-methylation were relatively comparable, -124.5 and -135.4 kcal/mol, respectively (Table III) , suggesting that the wild-type and mutant S-COMTs have a similar binding affinity for 2-OH-E 2 , which agreed well with our experimental data (Table II) . Similarly, the computed binding energy values for the binding interactions of 4-OH-E 2 with the wild-type and mutant S-COMTs for its 4-O-methylation were -122.9 and -138.5 kcal/mol, respectively (Table III) , which are also in agreement with our experimental data (Table II) .
Discussion
Earlier familial studies based on the measurement of COMT activity in red blood cells revealed that COMT is a polymorphic enzyme, with a bimodal/trimodel distribution pattern (39) . Moreover, the trait of the low COMT activity was found to be associated with a decreased thermostability of the enzyme preparation (22) (23) (24) . Following the subsequent cloning of the human COMT gene (4, 40, 41) , a number of single point mutations in the coding regions of this gene have been reported (listed in Table I ). Among them, the V108/ 158M polymorphism has been most extensively studied. Many epidemiological studies have shown that women, homozygous with the V108/158M mutant, have an increased risk of developing estrogen-associated cancers (21) (22) (23) (24) (25) (26) (27) . This polymorphism has also been suggested to be associated with an elevated risk of schizophrenia, obsessive-compulsive disorder, bipolar disorder, and Parkinson's disease in both genders (22) (23) (24) (28) (29) (30) (31) (32) . In addition to the known effects associated with non-synonymous mutations, polymorphism involving synonymous changes (such as H62H and L136L) has also been shown to cause a marked change in COMT and a representative substrate (2-OH-E 2 ). The enzymes are complexed with 2-OH-E 2 in the catalytic pocket in its geometry for 2-O-methylation. The figure is drawn using PyMOL software. Secondary structures are shown with colored ribbons with blue for N-terminus and red for C-terminus. AdoMet is colored red, 2-OH-E 2 , green and Mg 2+ , magenta. The amino acids at mutation sites (D51, S60 and K162 for wild-type S-COMT and G51, F60 and R162 for mutant S-COMT) are shown in white sticks. Hydrogens are omitted from AdoMet, 2-OH-E 2 and the amino acids. levels, largely due to reduced amounts of the COMT proteins being expressed (12) . These studies provide the basis for further studies to identify other non-synonymous and synonymous mutations/polymorphisms of the human COMT gene and particularly those that alter the catalytic activity of COMT and/or its protein levels.
In the present study, we identified a new haplotype of the human COMT gene with triplet point mutations (D51G/ S60F/K162R for S-COMT and D101G/S110F/ K212R for MB-COMT), and we have also selectively expressed the mutant enzymes in E. coli for the characterization of the catalytic properties. We found that the kinetic parameters (K M and V MAX ) of the mutant S-and MB-COMTs did not differ significantly from those of the wild-type enzymes when 2-OH-E 2 and 4-OH-E 2 were used as substrates. For instance, the mutant S-and MB-COMTs have similar K M values (3.3 and 2.6 μM, respectively) as the wild-type S-and MB-COMTs (3.6 and 3.2 μM, respectively) for the Omethylation of 2-OH-E 2 . In addition, the mutant S-COMT had almost the same regio-preference for the 2-O-methylation of 2-OH-E 2 over its 3-O-methylation as that of the wild-type S-COMT.
One of the notable differences between the mutant and wild-type human COMTs was the thermostability. While the wild-type human COMTs (S-and MB-COMT) are very stable after 2 h of pre-incubation at 37˚C, the mutant COMTs lost ~60% of their catalytic activity under the same preincubation conditions. Notably, earlier biochemical analyses of the V108M mutant and wild-type human S-COMTs also showed that whereas they had similar catalytic activity for the O-methylation of catechol estrogens in vitro, the mutant protein was more susceptible to heat inactivation (35, 36) . In these cases, since the mutant enzymes are more unstable under prolonged incubation at 37˚C (the physiological temperature), it is suggested that this will eventually result in decreased total levels of catalytically-active COMTs in a given tissue or cell.
In addition, we also noted a difference in the apparent K M values of the mutant and wild-type S-COMTs for the methyl donor AdoMet. Whereas the mutant S-COMT had a lower K M value than did the wild-type S-COMT when 2-OH-E 2 was used as substrate, this difference disappeared when 4-OH-E 2 was the substrate. As expected, the mutant and wildtype S-COMTs also had a different sensitivity to inhibition by AdoHcy, a demethylated AdoMet which binds to same pocket in the COMTs. The IC 50 value (18.4 μM) of AdoHcy for the mutant S-COMT was 3-fold higher than the IC 50 value (6.1 μM) for the wild-type S-COMT when 2-OH-E 2 was the substrate, but when 4-OH-E 2 was the substrate, the sensitivity of inhibition by AdoHcy was comparable (26.6 and 29.6 μM). Collectively, these data suggest that the mutant S-COMT has a higher binding affinity for AdoMet than does the wild-type S-COMT when 2-OH-E 2 is the substrate, and due to its higher binding affinity, the concentration of AdoHcy needed to compete for its binding site is proportionally higher.
To better understand the precise structural and functional differences between the D51G/S60F/K162R mutant of S-COMT and the wild-type protein, we have built the homology models of the mutant and wild-type S-COMTs for comparison. It is apparent that the overall secondary structure of the mutant enzyme and especially the structure of its catalytic site (built in two different ways) are very similar to those of the wild-type enzyme. Consistent with this observation, the calculated binding energy values (ΔE binding ) for the interactions of the mutant and wild-type enzymes with substrates were also comparable, which agreed well with the experimental data for the O-methylation of 2-OH-E 2 and 4-OH-E 2 . The overall structural similarities between the mutant and wildtype S-COMTs likely are attributable to the following two factors: i) The three mutant amino acid residues were found to be located at the surface regions of the protein and were relatively distanced from the catalytic site. ii) Two of the three mutations were located in the loop regions of the protein sequence (S60F in loop 3 and K162R in loop 11), and their presence did not alter any of the existing α-helical structures. Although D51 is located in the middle of α-helix 3, this mutation also did not cause a disruption of the original α-helical structure. Table III . The binding energy of 2-OH-E 2 and 4-OH-E 2 with the wild-type human S-COMT and the mutant S-COMT (D51G/S60F/K162R). 
-----------------------------------------------------------------------------------------------------Genotype Substrate Site of O-methylation ΔE binding -----------------------------------------------------------------------------------------------------
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ΔE binding was calculated using the following equation: ΔE binding = E complex -(E COMT + E substrate ), where E complex is the potentical energy for the complex of COMT with substrate, E COMT is the potential energy of the enzyme itself and E substrate is the potential energy for the substrate itself.
In summary, we have identified a new human COMT haplotype with triple point mutations, i.e., D51G/S60F/K162R for S-COMT and D101G/S110F/K212R for MB-COMT. The selectively-expressed S-and MB-COMT proteins have been biochemically characterized for their catalytic and kinetic properties. Although the catalytic activity of the mutant Sand MB-COMTs does not differ significantly from that of the wild-type enzymes when 2-OH-E 2 or 4-OH-E 2 is the substrate, the mutant COMTs have a lower thermostability compared to the wild-type proteins. The mutant and wildtype S-COMTs have different binding affinities for AdoMet and AdoHcy, depending on the substrate used.
